Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy

OncoImmunology

Volumn 4, Issue 6, 2015, Pages

  Mozzillo, Nicola ^a   Simeone, Ester ^a   Benedetto, Lucia ^a   Curvietto, Marcello ^a   Giannarelli, Diana ^b   Gentilcore, Giusy ^a   Camerlingo, Rosa ^a   Capone, Mariaelena ^a   Madonna, Gabriele ^a   Festino, Lucia ^a   Carac�, Corrado ^a   Di Monta, Gianluca ^a   Marone, Ugo ^a   Di Marzo, Massimiliano ^a   Grimaldi, Antonio M ^a   Mori, Stefano ^a   Ciliberto, Gennaro ^a   Ascierto, Paolo A ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Biomarker; Electrochemotherapy; Immuno oncology; Ipilimumab; Melanoma

Indexed keywords

B RAF KINASE; B7 ANTIGEN; BLEOMYCIN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; CELL PROLIFERATION; CLINICAL ARTICLE; COMPASSIONATE USE; CONTROLLED STUDY; CYTOTOXIC LYMPHOCYTE; DISEASE CONTROL; DRUG EFFICACY; ELECTROCHEMOTHERAPY; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LIFE EXPECTANCY; MALE; METASTATIC MELANOMA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; REGULATORY T LYMPHOCYTE; RETROSPECTIVE STUDY; SKIN DEFECT; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE;

EID: 84944463986     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1008842     Document Type: Article

References (44)

1. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. http://globocan.iarc.fr/Default.aspx. Accessed 22 April 2014
2. Robinson JK, Baker MK, Hillhouse JJ. New Approaches to Melanoma Prevention. Dermatol Clin 2012; 30: 405-12; PMID:22800548; http://dx.doi. org/10.1016/j.det.2012.04.006
3. American Cancer Society Cancer Facts and Figures 2013. http://www.cancer.org/research/cancerfactsfig ures/cancerfactsfigures/cancer-facts-figures-2013. Accessed 22 April 2014
4. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995; 182: 459-65; PMID:7543139; http://dx.doi.org/10.1084/ jem.182.2.459
5. Blank C, Kuball J, Voelkl S, Wiendl H, Becker B, Walter B, Majdic O, Gajewski TF, Theobald M, Andreesen R et al. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer 2006; 119: 317-27; PMID:16482562; http://dx.doi. org/10.1002/ijc.21775
6. O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic Tlymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 2007; 110: 2614-27; PMID: 18000991; http://dx.doi.org/10.1002/cncr.23086
7. Lipson EJ, Drake CG. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res 2011; 17: 6958-62; PMID:21900389; http://dx.doi. org/10.1158/1078-0432.CCR-11-1595
8. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
9. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-26; PMID:21639810; http://dx.doi.org/ 10.1056/NEJMoa1104621
10. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon R-A, Reed K et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369: 122-33; PMID:23724867; http://dx.doi.org/10.1056/ NEJMoa1302369
11. Sznol M, Kluger HM, Callahan MK, Postow MA, Gordon RA, Segal NH, Rizvi NA, Lesokhin AM, Atkins MB, Kirkwood JM et al. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). J Clin Oncol 2014; 32 (Suppl. 5): abstract LBA9003
12. Hiniker SM, Chen DS, Reddy S, Chang DT, Jones JC, Mollick JA, Swetter SM, Knox SJ. A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Transl Oncol 2012; 5: 404-7; PMID:23323154; http://dx.doi.org/10.1593/ tlo.12280
13. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012; 366: 925-31; PMID:22397654; http://dx.doi.org/10.1056/ NEJMoa1112824
14. Grimaldi AM, Simeone E, Giannarelli D, et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology 2014; 3:e28780; doi:10.4161/ onci.28780
15. Puzanov I, Milhem MM, Andtbacka RHI, Minor DR, Hamid O, Li A, Chastain M, Gorski K, Anderson A, Vanderwalde AM et al. Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. J Clin Oncol 2014; 32:5s, (suppl; abstr 9029); PMID:24190110; http://dx.doi.org/10.1200/ JCO.2013.49.4757
16. Marty M, Sersa G, Garbay JR, Gehl J, Collins CG, Snoj M, Billard V, Geertsen PF, Larkin JO, Miklavcic D, et al. Electrochemotherapy-An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. EJC Supplements 2006; 4: 3-13; http://dx.doi.org/ 10.1016/j.ejcsup.2006.08.002
17. Mir LM, Gehl J, Sersa G, Collins CG, Garbay J-R, Billard V, Geertsen PF, Rudolf Z, O'Sullivan GC, Marty M. Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes. EJC Supplements 2006; 4: 14-25; http://dx.doi.org/10.1016/j. ejcsup.2006.08.003
18. Queirolo P, Marincola F, Spagnolo F. Electrochemotherapy for the management of melanoma skin metastasis: a review of the literature and possible combinations with immunotherapy. Arch Dermatol Res 2014; 306: 521-6; PMID:24682537; http://dx.doi.org/10.1007/ s00403-014-1462-x
19. Mali B, Jarm T, Snoj M, Sersa G, Miklavcic D. Antitumor effectiveness of electrochemotherapy: a systematic review and meta-analysis. Eur J Surg Oncol 2013; 39: 4-16; PMID:22980492; http://dx.doi.org/10.1016/j. ejso.2012.08.016
20. Carac� C, Mozzillo N, Marone U, Simeone E, Benedetto L, Di Monta G, Di Cecilia ML, Botti G, Ascierto PA. Long-lasting response to electrochemotherapy in melanoma patients with cutaneous metastasis. BMC Cancer 2013; 13: 564; PMID: 24289268; http://dx. doi.org/10.1186/1471-2407-13-564
21. Campana LG, Valpione S, Mocellin S, Sundararajan R, Granziera E, Sartore L, Chiarion-Sileni V, Rossi CR. Electrochemotherapy for disseminated superficial metastases from malignant melanoma. Br J Surg 2012; 99: 821-30; PMID:22508342; http://dx.doi.org/ 10.1002/bjs.8749
22. Sersa G, Cemazar M, Menart V, Gaberc-Porekar V, Miklavcic D. Anti-tumor effectiveness of electrochemotherapy with bleomycin is increased by TNF-alpha on SA-1 tumors in mice. Cancer Lett 1997; 116: 85-92; PMID:9177462; http://dx.doi.org/10.1016/S0304-3835(97)00170-5
23. Mir LM, Orlowski S, Belehradek J Jr, Paoletti C. Electrochemotherapy potentiation of antitumour effect of bleomycin by local electric pulses. Eur J Cancer 1991; 27: 68-72; PMID:1707289; http://dx.doi.org/ 10.1016/0277-5379(91)90064-K
24. Mir LM, Orlowski S, Poddevin B, Belehradek J Jr. Electrochemotherapy tumor treatment is improved by interleukin-2 stimulation of the host's defences. Eur Cytokine Netw 1992; 3: 331-4; PMID:1379837
25. Calvet CY, Famin D, Andr� FM, Mir LM. Electrochemotherapy with bleomycin induces hallmarks of immunogenic cell death in murine colon cancer cells. OncoImmunology 2014; 3: e28131; PMID:25083316; http://dx.doi.org/10.4161/ onci.28131
26. Simeone E, Gentilcore G, Giannarelli D, Grimaldi AM, Carac� C, Curvietto M, Esposito A, Paone M, Palla M, Cavalcanti E et al. Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother 2014; 63:675-83; PMID:24695951; http://dx.doi.org/10.1007/s00262-014-1545-8
27. O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, Queirolo P, Lundgren L, Mikhailov S, Roman L et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 2010; 21: 1712-7; PMID: 20147741; http://dx.doi.org/10.1093/annonc/mdq013
28. Queirolo P, Spagnolo F, Ascierto PA, Simeone E, Marchetti P, Scoppola A, Del Vecchio M, Di Guardo L, Maio M, Di Giacomo AM et al. Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. J Neurooncol 2014; 118: 109-16; PMID:24532241; http://dx.doi.org/10.1007/s11060-014-1400-y
29. Hersh EM, O'Day SJ, Powderly J, Khan KD, Pavlick AC, Cranmer LD, Samlowski WE, Nichol GM, Yellin MJ, Weber JS. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapyna�ve patients with advanced melanoma. Invest New Drugs 2011; 29: 489-98; PMID:20082117; http://dx. doi.org/10.1007/s10637-009-9376-8
30. Di Giacomo AM, Ascierto PA, Pilla L, Santinami M, Ferrucci PF, Giannarelli D, Marasco A, Rivoltini L, Simeone E, Nicoletti SV et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBITM1): an open-label, single-arm phase 2 trial. Lancet Oncol 2012; 13: 879-86; PMID:22894884; http://dx. doi.org/10.1016/S1470-2045(12)70324-8
31. Burnette B, Fu Y-X, Weichselbaum RR. The confluence of radiotherapy and immunotherapy. Front Oncol 2012; 2: 143; PMID:23087904; http://dx.doi.org/ 10.3389/fonc.2012.00143
32. Campana LG, Testori A, Mozzillo N, Rossi CR. Treatment of metastatic melanoma with electrochemotherapy. J Surg Oncol 2014; 109:301-7; PMID:24678530; http://dx.doi.org/10.1002/ jso.23512
33. Gehl J, Anderson MH, Hastrup N, Straten PT, Geertsen PF. Electrochemotherapy with low-dose IL-2 in the treatment of disseminated malignant melanoma: clinical and paraclinical evidence of systemic immune response. Proc Am Soc Clin Oncol 2003; 22 (abstract 2906)
34. Gerlini G, Sestini S, Di Gennaro P, Urso C, Pimpinelli N, Borgognoni L. Dendritic cells recruitment in melanoma metastasis treated by electrochemotherapy. Clin Exp Metastasis 2013; 30: 37-45; PMID:22735940; http://dx.doi.org/10.1007/s10585-012-9505-1
35. Ku GY, Yuan J, Page DB, Schroeder SEA, Panageas KS, Carvajal RD, Chapman PB, Schwartz GK, Allison JP, Wolchok JD. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 2010; 116: 1767-75; PMID:20143434; http://dx.doi.org/10.1002/ cncr.24951
36. Liakou CI, Kamat A, Tang DN, Chen H, Sun J, Troncoso P, Logothetis C, Sharma P. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci USA 2008; 105: 14987-92; PMID:18818309; http://dx.doi.org/10.1073/ pnas.0806075105
37. Weber JS, Dummer R, de Pril V, Lebb� C, Hodi FS, MDX010-20 Investigators. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 2013; 119: 1675-82; PMID:23400564; http:// dx.doi.org/10.1002/cncr.27969
38. Ascierto PA, Simeone E, Sileni VC, Pigozzo J, Maio M, Altomonte M, Del Vecchio M, Di Guardo L, Marchetti P, Ridolfi R et al. Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med 2014; 12: 116; PMID:24885479; http://dx.doi.org/ 10.1186/1479-5876-12-116
39. Matthiessen LW, Chalmers RL, Sainsbury DC, Veeramani S, Kessell G, Humphreys AC, Bond JE, Muir T, Gehl J. Management of cutaneous metastases using electrochemotherapy. Acta Oncol 2011; 50: 621-9; PMID:21574833; http://dx.doi.org/10.3109/ 0284186X.2011.573626
40. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebb� C, Maio M, Binder M, Bohnsack, O, Nichol G et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15: 7412-20; PMID:19934295; http://dx.doi.org/10.1158/1078-0432.CCR-09-1624
41. Del Vecchio M, Di Guardo L, Ascierto PA, Grimaldi AM, Sileni VC, Pigozzo J, Ferraresi V, Nuzzo C, Rinaldi G, Testori A et al. Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. Eur J Cancer 2014; 50: 121-7; PMID:24100024; http://dx.doi.org/10.1016/j. ejca.2013.09.007
42. Di Giacomo AM, Danielli R, Calabr� L, Bertocci E, Nannicini C, Giannarelli D, Balestrazzi A, Vigni F, Riversi V, Miracco C et al. Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Cancer Immunol Immunother 2011; 60: 467-77; PMID:21170646; http://dx.doi.org/10.1007/ s00262-010-0958-2
43. Di Giacomo AM, Calabr� L, Danielli R, Fonsatti E, Bertocci E, Pesce I, Fazio C, Cutaia O, Giannarelli D, Miracco C et al. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme. Cancer Immunol Immunother 2013; 62: 1021-8; PMID:23591982; http://dx.doi.org/10.1007/s00262-013-1418-6
44. Queirolo P, Simeone E, De Galitiis F, Di Guardo L, Marconcini R, Di Giacomo AM, Ferraresi V, De Rosa F, Guida Stragliotto MS. Efficacy and safety data from patients with advanced melanoma and brain metastases participating in the European ipilimumab expanded access programme (EAP) in Italy. Ann Oncol 2012; 23 (suppl. 9), ix369 (abstract 1132)